Profile

PhD (SEU), Associate Research Fellow. His research focus is on design, synthesis and pharmacological activity of antitumor drugs.As of December 2024, he has published 10 peer-reviewed papers in international journals, all of which he serves as the first author/co first author, mainly in top journals such as Chemical Science (IF: 9.969), European Journal of Medicinal Chemistry (IF: 7.088), Chemical Communications (IF: 6.29), Inorganic Chemistry (IF: 5.436), Bioorganic Chemistry (IF: 5.307), he has also applied for 1 invention patent which has been licensed.

He is engaged in industry university research work in the field of pharmacy, and has won the following honors:

(1)    The 2nd National Postdoctoral Innovation and Entrepreneurship Competition in 2023 ▪ Bronze Award (10th place nationwide).

(2)    Awarded National Excellent Postdoctoral Fellow in Innovation and Entrepreneurship in 2023.

(3)    The 7th Maker Guangdong Biomedical and Health SME Innovation and Entrepreneurship Competition, Zhuhai Maker Group ▪ First prize in 2023.

(4)    The Top 50 Maker Groups in Guangdong Province in the 7th Maker Guangdong Competition in 2023.

(5)    The 11th China Innovation and Entrepreneurship Competition (Guangdong Division) and Zhuhai Science and Technology Innovation Cup Innovation and Entrepreneurship Competition ▪ Third Prize in 2022.

(6)    Awarded Xiangshan Entrepreneurship Talent in Xiangzhou District, Zhuhai City.

(7)    The 11th China Innovation and Entrepreneurship Competition (Guangdong Division) and Zhuhai Science and Technology Innovation Cup Innovation and Entrepreneurship Competition ▪ Third Prize in 2022.

(8)    The 7th Jiangsu Association for Science and Technology Youth Member Innovation and Entrepreneurship Competition ▪ Second Prize in 2022.

(9)    The Science and Technology Innovation Jiangsu Innovation and Entrepreneurship Competition in Jiangsu Province ▪ Third Prize in 2022.

(10) Awarded High level Entrepreneurial Talent in the Nanjing Zijinshan Talent Jiangning Baijiahu Talent Plan in  2021.

(11) Awarded Outstanding Postdoctoral Fellow in Jiangsu Innovation and Entrepreneurship in 2021.

Education& Professional Experience：

2023.06 - present

Associate Research Fellow, Institute for Advanced and Applied Chemical Synthesis, Jinan University, China

2021.06 - 2023.06

Post-doctoral Research Fellow/ Associate Research Fellow

School of Chemistry and Chemical Engineering, Southeast University, Nanjing, China

2019.04 - 2021.06

Deputy General Manager

Nanjing JunRuo Biomedical Research Institute Co., Ltd., Nanjing, China

2018.07 - 2019.04

Management Trainee

Zhejiang Yangshengtang Natural Medicine Research Institute Co., Ltd, Hangzhou, China

2014.09 - 2018.06

PhD of Engineering (Specialty: Chemical Engineering and Technology)

School of Chemistry and Chemical Engineering, Southeast University, Nanjing, China

2011.09 - 2014.06

Master of Science (Specialty: Pharmaceutical chemistry)

School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China

2007.09 - 2011.06

Bachelor of Science (Specialty: Pharmaceutical Science Base Class)

College of Pharmacy, China Pharmaceutical University, Nanjing, China

Representative Publications in Recent 5 Years：

1.       Zichen Xu, Bin Zhang, Zhikun Liu, Shaohua Gou*. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors. Eur. J. Med. Chem.2022, 224, 114875-114886.

影响因子（7.088） A1一区

2.       Zichen Xu, Yongzhi Yu, Jian Zhao, Zhixin Liao, Yanyan Sun, Si Cheng, Shaohua Gou*. A unique chemo-photodynamic antitumor approach to suppress hypoxia via ultrathin graphitic carbon nitride nanosheets supported a Platinum(IV) prodrug. Inorg. Chem. 2022, 61, 20346-20357.

影响因子（5.436） A1一区

3.       Bin Zhang^‡; Zichen Xu^‡; Wen Zhou; Zhixin Liao; Shaohua Gou*. A light-controlled multi-step drug release nanosystem targeting tumor hypoxia for synergistic cancer therapy.Chem. Sci. 2021, 12, 11810-11820.

影响因子（9.969） A1一区

4.       Bin Zhang^‡; Zichen Xu^‡; Qingqing Liu; Shengjin Xia; Zhikun Liu; Zhixin Liao; Shaohua Gou*. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation. Bioorg. Chem.2021, 117, 105420-105431.

影响因子（5.307） A1一区

5.       Zichen Xu; Jian Zhao; Gang Xu; Shaohua Gou*. Novel hypoxia-targeting Pt(IV) prodrugs. Chem. Commun. 2017, 53, 3749-3752.

影响因子（6.065） A1二区

6.       Zichen Xu; Weiwei Hu; Zhimei Wang; Shaohua Gou*. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1. Eur. J. Med. Chem. 2017, 141, 211-220.

影响因子（7.088） A1一区

7.       Jian Zhao^‡; Zichen Xu^‡; Jing Lin; Shaohua Gou*. Exploring the Hydrolytic Behavior of the Platinum(IV) Complexes with Axial Acetato Ligands. Inorg. Chem.2017, 56, 9851-9859.

影响因子（5.436） A1一区

8.       Zichen Xu. Patent:Preparation and application of antitumor immunomodulatory conjugate, CN: ZL 2019 1 0593560.5: B

‡Co first author；*Corresponding author

Contact：

Room 619, the Second Science and Technology Building, Jinan University, Guangzhou

Email: xuzc224@jnu.edu.cn